1 results match your criteria: "1 Corporate Center[Affiliation]"

Dissimilarity-based approaches to compound acquisition.

Curr Opin Chem Biol

June 2008

Eli Lilly and Company, 1 Corporate Center, Indianapolis, IN 46285, USA.

The concept of molecular diversity has been integrated in drug discovery efforts for many years. Applications of molecular diversity have been used to identify compounds for screening and to select compounds to augment proprietary collections. These early efforts were crude and suffered from a number of faults, but their evolution has, over the years, led to an improvement in the computational procedures used to identify new commercial compounds for acquisition.

View Article and Find Full Text PDF